1 2 3	Virologic, clinical, and immunological characteristics of a dengue virus 3 human challenge model
З Л	
5 6 7	Adam T. Waickman <sup>1,2</sup> , Krista Newell <sup>1</sup> , Joseph Q. Lu <sup>1,2</sup> , HengSheng Fang <sup>1</sup> , Mitchell Waldran <sup>1</sup> , Chad Gebo <sup>1</sup> , Jeffrey R. Currier <sup>3</sup> , Heather Friberg <sup>3</sup> , Richard G. Jarman <sup>3</sup> , Michelle D. Klick <sup>2</sup> , Lisa A. Ware <sup>2</sup> , Timothy P. Endy <sup>1</sup> , Stephen J. Thomas <sup>1,2</sup>
8 9 10	<sup>1</sup> Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
11 12 13	<sup>2</sup> Institute for Global Health and Translational Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
14 15 16	<sup>3</sup> Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
17 18 19	
20	
21	
22	
23	
24	
25	
26	
21	
28	
29 20	
30 31	
31	
32	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	Keywords: DENV, dengue human infection model, inflammation, infection

#### 47 Abstract (150 words):

#### 48

- 49 Dengue human infection models present an opportunity to explore a vaccine, antiviral, or
- 50 immuno-compound's potential for clinical benefit in a controlled setting. Herein, we report the
- 51 outcome of a phase 1, open-label assessment of a DENV-3 challenge model. In this study, 9
- 52 participants received a subcutaneous inoculation with 0.5ml of a  $1.4 \times 10^3$  PFU/ml suspension of
- 53 the DENV-3 strain CH53489. All subjects developed RNAemia within 7 days of inoculation,
- 54 with peak titers ranging from  $3.13 \times 10^4$  to  $7.02 \times 10^8$  GE/ml. Symptoms and clinical lab
- abnormalities consistent with mild dengue infection were observed in all subjects. DENV-3
- 56 specific seroconversion was observed by 14 days after inoculation, along with DENV-3 specific
- 57 memory T cell responses. RNAseq and serum cytokine analysis revealed the presence of an
- antiviral transcriptional and cytokine response to infection that overlapped with the period of
- 59 viremia. The magnitude and frequency of clinical and immunologic endpoints correlated with an
- 60 individual's peak viral titer.
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68 69
- 70
- 70
- 72
- 73
- 74
- 75 76
- 77
- 78
- 79
- 80
- 81
- 82

#### 83 **INTRODUCTION**

84

85 Dengue is an expanding global public health threat in predominantly tropical and subtropical

86 regions [1, 2]. Dengue is caused by infection with any of the four DENV types; each being

87 virologically related but genetically and antigenically distinct [3]. Aedes mosquito species are the

- 88 primary vectors of DENV transmission and changes in climate have expanded their habitat
- 89 allowing for local transmission in historically more temperate regions [4, 5].
- 90

91 It is estimated there are up to 400 million DENV infections every year, with more than 90

- 92 million resulting in clinically relevant disease [1, 2, 6]. Infection may result in an asymptomatic
- 93 or subclinical infection or classic dengue fever [3, 7]. Severe dengue occurs in a minority of
- 94 infections, approximately 2-4% of people experiencing a sequential infection with a different
- 95 DENV type more than 18 months following their first infection [8-10]. Severe dengue may
- 96 manifest as plasma leakage, hemorrhage, end organ dysfunction, and death [8, 9, 11]. Current
- 97 treatment is primarily based on symptom relief and judicious intravascular volume replacement
- 98 with fluids [12, 13].
- 99

100 Currently, there are no antivirals approved for the prevention or treatment of DENV infections.

101 There are also no immuno-compounds (i.e., monoclonal antibodies) approved for the prevention

- 102 or treatment of dengue. A single dengue vaccine (Sanofi Pasteur, Dengvaxia<sup>®</sup>) has been
- 103 approved for use in numerous countries, but uptake has been low due to the need to assess
- 104 dengue serostatus prior to vaccination, and an observed safety signal in children who were
- 105 seronegative at the time of vaccination [14-16]. Takeda Vaccines has recently received approval
- 106 for use of their vaccine (TAK-003) in Indonesia without the restriction of needing to confirm
- 107 serostatus prior to vaccination [17-19]. The company is pursuing additional regulatory approvals. 108
- 109 Developing countermeasures against dengue has been challenging for a number of reasons,
- 110 including; 1) the existence of four DENVs, each capable of causing disease and death, 2) an
- 111 incomplete understanding of what constitutes an immuno-protective versus immuno-pathologic
- 112
- profile prior to infection; 3) the inability to precisely measure homotypic, non-cross reactive
- 113 DENV immune responses; and 4) the absence of an animal model of disease which accurately
- 114 recapitulates the human infection experience [20, 21].
- 115
- 116 For these reasons, a consortium of investigators has continued over a century of work devoted to
- 117 developing a safe dengue human infection model (DHIM) [22]. The intent of the DHIM is to
- 118 expose healthy volunteers to under-attenuated DENVs and create a mild and uncomplicated
- 119 dengue illness. The objective is to intensely study signs and symptoms of dengue, clinical lab
- 120 abnormalities, virologic, and innate and adaptive immune responses. Knowing the exact
- 121 infecting DENV type and time of exposure allows investigators to explore, in detail, the kinetics
- 122 of clinical, virologic, serologic, and immunologic responses to infection.
- 123
- 124 The DHIM is not intended to study moderate or severe dengue, but to drastically improve upon
- 125 the limitations of current small animal and non-human primate models of uncomplicated dengue
- 126 disease. A safe and consistently performing DHIM representing each of the four DENV types
- 127 would be a powerful tool supporting the development of dengue vaccines, treatments, and non-
- 128 vaccine prophylactics. A DHIM capable of assessing, early in development, the potential for

129 clinical benefit of a countermeasure could prevent thousands of volunteers having to be exposed

- 130 to ineffective countermeasure candidates.
- 131

132 In this manuscript we describe our clinical characterization of a DENV-3 DHIM viral strain. In

this study, we screened and enrolled 9 flavivirus naïve, healthy adults. Each volunteer was

- 134 subcutaneously inoculated with 0.5ml of a  $1.4 \times 10^3$  PFU/ml suspension of the DENV-3 strain
- 135 CH53489 manufactured under Good Manufacturing Practices. The trial was conducted following
- 136 U.S. Food and Drug Administration acceptance of an Investigational New Drug application and
- 137 local Institutional Review Board approval. Following inoculation, volunteers were assessed daily
- 138 or every other day for 28 days. Follow-up visits also occurred at more remote timepoints out to
- 139 180 days. Blood samples were collected to assess safety and virologic, serologic, and
- 140 immunologic responses to infection.141

# 142 **RESULTS**

143

144 Virologic characteristics of CH53489 strain DENV-3 challenge. Nine participants

145 (Supplemental Table 1) were enrolled in this study to receive a single subcutaneous inoculation

146 with 0.5ml of a  $1.4 \times 10^3$  PFU/ml suspension of the DENV-3 strain CH53489 [23, 24].

- 147 Participants in this study were evaluated daily for the first 14 days after inoculation either in-
- 148 person or by phone, then every other day until 28 days post virus inoculation with additional
- 149 visits on days 90 and 180 post infection (**Supplemental Figure 1**). Participants were admitted to
- 150 SUNY Upstate Medical University Hospital for observation if they met pre-defined
- 151 hospitalization criteria. Six of nine study participants were admitted for observation during the
- 152 course of the study. As with previous DENV-1 challenge studies, all participants who became ill
- were managed with oral fluids, acetaminophen, and an anti-nausea medication if required. No
- 154 intravenous access was required. In the event of hospitalization, study participants were shifted 155 to an alternative sample collection schedule where safety and research blood draws were
- 156 collected daily for the duration of the hospital stay and additional research draws collected three-

and seven-days post discharge. All nine enrolled participants completed the study per protocol

- and were included in the subsequent virologic and immunologic analyses.
- 159

160 All study participants developed detectable RNAemia and viremia as assessed by qRT-PCR and

- 161 Vero cell-based plaque assay, respectively, while 8 of 9 study participants experienced
- 162 quantifiable NS1 antigenemia (Figure 1A, Figure 1B, Figure 1C). The incubation period (time
- 163 from infection to detectable RNAemia) ranged from 3 to 6 days (mean 4.1 days post challenge)
- 164 (**Figure 1D**), with peak viral loads occurring 6 to 8 days post challenge (mean 6.7 days post
- 165 challenge) (**Figure 1E**). Peak viral load ranged from  $3.13 \times 10^4$  to  $7.02 \times 10^8$  genome equivalents

166 (GE)/mL, or  $5.3 \times 10^3$  to  $3.0 \times 10^7$  plaque forming units (PFU)/mL of serum, with detectible

- 167 viremia (day of first detection until first day below detection) lasting 4 to 11 days (mean of 7.3
- 168 days). DENV NS1 antigenemia was detected on average 3.1 days later than RNAemia or
- viremia, with the day of detectible NS1 antigenemia ranging between 6 to 12 days post challenge
- 170 (mean 7.3 days), persisting for an average (mean) of 12.25 days across all NS1 antigen positive
- 171 study participants (**Fig. 1C**).
- 172
- 173 **Clinical characteristics of CH53489 strain DENV-3 challenge.** Within the first 14 days
- 174 following inoculation 9/9 study participants reported at least one solicited systemic AE. Rash

- 175 was observed in 7/9 subjects, which was evident for between 3 and 20 days per individual
- 176 (median of 9 days), with 4/9 reporting severe rash based on the percent of body surface area
- 177 involved (Figure 2A). Fatigue was described by 7/9 subjects, lasting for 3-12 days (median of 6
- 178 days) (Figure 2B). Headache was described by 8/9 subjects and was experienced for 1 to 11
- 179 days per subject (median of 3 days) (Figure 2C). Fever defined as a temperature equal to or
- 180 greater than 100.4°C was observed in 8/9 individuals, lasting for 1 to 5 days per subject
- 181 (median 2 days), with one subject experiencing severe ( $\geq 102.1^{\circ}$ C) fever (**Figure 2D**).
- 182

183 All study participants had at least 1 laboratory abnormality between days 1 and 28 post DENV-3

- 184 strain CH53489 challenge, the majority of which were mild or moderate. At least 1 severe
- 185 laboratory abnormality was reported by 5 of the 9 participants. Elevated liver enzyme levels
- 186 (ALT/AST) were observed in 5/9 study participants with 2 individuals classified as severe and
- all returning to normal ranges within 30 days post challenge (**Figure 3A, Figure 3B**). No
- hemoconcentration was observed in any subject during the course of the study (**Figure 3C**).
- 189 Lymphopenia was observed in 9/9 subjects (3 severe), while neutropenia was observed in 7/9
- subjects (2 severe), and thrombocytopenia observed in 4/9 study participants (1 severe) (Figure 3D, Figure 3E, Figure 3F).
- 192

193 Kinetics and specificity of DENV-3 elicited humoral immunity. Having established the 194 virologic and clinical features of CH53489 human challenge we next assessed the induction of

- 195 DENV-3 specific adaptive immunity. Using a virion-capture ELISA assay we observed the
- 196 induction of a robust DENV-3 specific IgM response in all participants first detectible between
- days 9 and 14 post infection and persisting above baseline in 8/9 subjects for at least 90 days
- 198 (Figure 4A, Figure 4B). A transient DENV-3 specific IgA response was also observed starting
- between days 12 and 15 post challenge, dropping below the threshold of detection in 7/9 subjects
  by day 90 post infection (Figure 4A, Figure 4B). DENV-3 specific IgG was detected in
- 201 circulation observed starting between days 14 and 28 post challenge, remaining above the
- threshold of detection in 8/9 for at least 90 days post infection (**Figure 4A, Figure 4B**).
- 203

204 In addition to assessing the abundance of virion-specific antibodies, the abundance of NS1-

- 205 specific antibodies elicited by CH53489 infection were quantified using cell-based NS1
- 206 opsonization assay. We utilized a CEM.NK<sup>R</sup> cell line that was engineered to stably express
- 207 DENV-3 NS1 and quantified the abundance of anti-NS1 opsonizing antibodies using flow
- 208 cytometry (Supplemental Figure 3). Robust induction of anti-NS1 IgM antibodies was observed
- 209 in all study participants first starting between days 8 and 28 post infection, with IgG isotype
- 210 responses appearing later and persisting through day 90 post infection (Figure 4C, Figure 4D).
- 211 Only modest and transient anti-NS1 IgA antibody titers were observed following CH53489
- 212 challenge (**Figure 4C, Figure 4D**).
- 213
- 214 Consistent with the robust humoral immune response elicited by CH53489 challenge, IFN-γ
- ELISPOT analysis of PBMC collected from study participants on days 0, 28 and 90 post
- 216 infection demonstrated the presence of a significant adaptive cellular immune response to
- 217 infection. Stimulation with overlapping peptide pools spanning the E, NS1, NS3, and NS5
- 218 proteins demonstrated the induction of significant cellular immune responses against all antigens
- included in the analysis, which NS3, NS5 and E proteins exhibiting higher responses on average
- than NS1(Figure 4E, Supplemental Figure 4). In their totality these results demonstrate that

221 CH53489 challenge results in the development of robust DENV-3 specific humoral and cellular immunity that persists for at least 90 days post infection. 222

223

224 **Transcriptional profiling of CH53489-elicited immune activation.** In light of the robust 225 adaptive immune response elicited by CH53489 challenge we next endeavored to define the early transcriptional profile of DENV-3 elicited inflammation. Accordingly, we performed 226 227 RNAseq analysis on whole blood samples collected on or around days 0, 6, 8, 10, 14 and 28 post 228 CH53489 challenge in all 9 study participants. These time points were selected to capture both 229 the peak of viral replication (days 6-8 post infection) as well as the days when the induction of 230 the adaptive immune response was predicted to occur (day 10-14). Due to the adaptive nature of 231 the study protocol sample collections were not synchronous across all study participants. 232 Samples were binned into the nearest common study day (0, 6, 8, 10, 14, or 28) for subsequent

- 233 analysis (Supplemental Table 2).
- 234

235 Robust transcriptional deviations away from the day 0 transcriptional baseline were observed on

236 days 6, 8, 10, and 14 post infection, with all participants returning to a baseline transcriptional

237 state by day 28 post infection (Figure 5A). A total of 205 (196 upregulated, 9 downregulated),

238 302 (247 upregulated, 55 downregulated), 245 (195 upregulated, 50 downregulated) and 295

239 (267 upregulated, 28 downregulated) differentially expressed genes were observed on days 6, 8,

240 10, and 14, receptively (Figures 5B-E, Supplemental Tables 3-6). No differentially expressed

- 241 gene were observed on day 28 relative to day 0. Significant overlap was observed between the
- 242 differentially expressed genes detected on days 6, 8, and 10, while day 14 was characterized by a
- 243 mostly independent set of differentially expressed gene products (DEGs) (Figure 5F, 244 Supplemental Figure 5).
- 245

Ingenuity Pathway Analysis (IPA) of the DEGs identified in this study revealed that days 6, 8, 246 247 and 10 were dominated by the expression of gene products associated with interferon signaling,

248 chemokine/cytokine production, and the induction of antiviral responses (Table 1,

249 Supplemental Figure 6, Supplemental Tables 7-9). Gene pathways consistent with nascent B 250 cell activation and antibody production were also observed on days 10 and 14 post DENV-3

- 251 infection, with the day 14 gene profile dominated by terms associated with mitotic cell division
- 252 and lymphocyte proliferation (Table 1, Supplemental Figure 6, Supplemental Tables 9-10).
- 253 Consistent with these transcriptional profiles, elevated levels of IL-1Ra, IL-8, IFN- $\beta$ , IL-10, and
- 254 IFN- $\alpha$ 2a were observed in serum collected from subjects on days 6, 8 and 10 post challenge
- 255 (Supplemental Figure 7), while IFN- $\gamma$ , IL-10, and IL-9 were additionally detected starting on
- day 10 post infection (Supplemental Figure 8). No statistically significant differences in 256
- 257 VEGFA, TNFα, MIP-1a, GM-CSF, MCP1, IL-1β, IL-12p70, G-CSF, IL-6, IL-4 or IL-5 levels
- 258 were observed (Supplemental Figure 9).
- 259

260 To provide additional insight into the kinetics and relative magnitude of DENV-3 elicited 261 inflammation captured in the study we utilize a previously described DENV transcriptional

262 inflammation index to score each visit for each subject. Using this metric, the transcriptional 263

- signature of DENV-elicited inflammation peaked in all individuals between days 6 and 8 post
- 264 challenge, returning to near baseline levels by day 14 post challenge mirroring the kinetics of 265
- viremia observed in this study (Figure 4G). Furthermore, the abundance of unique IGH clones 266 assembled from the unenriched RNAseq data – a surrogate indicator of activated B cell

frequency – exhibited a significant increase from baseline starting on day 10 post infection,
peaking in all individuals on day 14, and returning to baseline by day 28 (Figure 5H).

269

270 **DENV-3 elicited plasmablast profiling.** In light of the robust B cell activation profile observed

- by RNAseq following CH53489 infection we endeavored to better define the clonal and
- transcriptional diversity of activated B cells (plasmablasts) elicited by DENV-3 infection in the
- study. To this end, CD38+CD27+ plasmablast-phenotype CD19+ B cells were sorted from the
- 274 PBMC of four subjects with the most robust B cell activation profile by as defined by RNAseq
- analysis (**Figure 6A, supplemental Figure 10**). After sorting, these purified plasmablasts were
- subjected to scRNAseq analysis using the 10xGenomics platform. This resulted in the capture of
- 15,717 DENV-elicited plasmablasts with full-length/paired immunoglobulin sequences.
- 278
- 279 Consistent with our previously published report analyzing the plasmablast profile elicited by
- 280 natural primary DENV infection [25], three of the four subjects included in this analysis
- 281 exhibited a significant IgA1/IgM isotype bias with numerous large/expanded clonal families,
- while one subject exhibited a more IgG1/IgM isotype bias with significantly less clonal
- 283 expansion (Figure 6B, Figure 6C, Figure 6D). Many clonal families were observed with
- 284 members with IgM, IgA, and IgG Fc regions (**Figure 6C**, **Figure 6D**). Relatively low levels of 285 somatic hypermutation (SHM) were observed in IgM and IgG isotype antibodies captured in this
- analysis, with IgA isotype antibodies on average exhibited significantly higher SHM burdens
- than their IgM and IgG counterparts.
- 288

289 Virologic and immunologic correlates of clinical dengue. We next endeavored to clarify the 290 correlative relationships between the individual virologic, clinical, and immunologic parameters 291 captured in this analysis. We selected three virologic parameters (peak RNAemia, viremia, and 292 NS1 antigenemia), four clinical parameters (days with rash, fatigue, headache, or fever), five 293 clinical labs (AUC of ALT, AST, WBC, neutrophil and platelet counts outside of normal range), 294 seven immunologic parameters (DENV-specific IgM/IgA/IgG AUC, NS1-specific IgM/IgA/IgG 295 AUC, and day 90 ELISPOT counts), five serum cytokine features (IL-1Ra, IP-10, IFN-A2a, 296 IFNg, and IL-10 AUC), and two transcriptional features (inflammation score and number of peak 297 annotated IGH clones) for inclusion in this analysis (Figure 7A).

298

All virologic parameters exhibited a high degree of correlation with multiple clinical parameters such as number of days with fever and ALT/AST levels (**Figure 7A, Figure 7B, Figure 7C**). In addition, peak viral loads correlated with DENV-specific IgM and IgG titers, and anti-NS1 IgG titers (**Figure 7A, Figure 7D, Figure 7E**). These results support a model wherein the incidence and severity of mild DENV-elicited clinical pathology – as well as the magnitude of DENV-

- 304 elicited adaptive immunity is directly proportional to viral burden in previously flavivirus
- 305 naïve individuals.
- 306
- 307

# 308 **<u>DISCUSSION</u>**

- 309
- 310 In this study we precisely define the virologic, immunologic, and clinical features associated
- 311 with a primary DENV-3 infection in flavivirus-naïve adults. This includes the kinetics and
- 312 composition of the innate, humoral, cellular, and transcriptional responses elicited by

313 experimental DENV-3 infection, as well as the virologic and clinical features of DENV-3

- infection in 9 individuals inoculated with the under-attenuated DENV-3 strain CH53489. A
- notable feature of the results presented in our current study is the strong correlation observed
- between peak viral load and the frequency and magnitude of the clinical and immunological
- features elicited by DENV-3 infection. While the relationship between peak viral load, symptom
- 318 severity, and subsequent anti-DENV immune profiles has been well established in individuals 319 experiencing clinically apparent dengue [7], to our knowledge this is the first time this
- relationship has been extended to include individuals with mild or asymptomatic primary DENV
- infections. Importantly, these results support the utility of dengue human challenge models in
- evaluating the potential clinical benefit of candidate anti-dengue countermeasures where
- 323 reduction in disease burden through the reduction in viral replication is an objective.
- 324

325 In addition to the spectrum of virologic and clinical features of primary DENV-3 infection

- 326 captured in this analysis, several notable immunologic responses to CH53489 infection were
- 327 observed. This includes a robust IgA1-biased plasmablast response after the resolution of acute
- 328 viremia and infection-elicited inflammation. The presence of an IgA-dominated plasmablast
- 329 response following primary DENV infection has now been described by multiple groups using
- 330 several different analytic approaches [25-28]. However, the origin of this IgA biased response
- remains unclear. The extensive hypermutation burden present in these IgA class-switched
- 332 plasmablasts might suggest that these cells arose from a pool of pre-existing IgA1 class-switched
- memory B cells that cross-react with DENV antigens. However, data presented in this study
- suggest this might not be the case, as B cell clones that have class-switched to IgM, IgG, and IgA
   are observed. These results are more consistent with a model wherein the IgA1 isotype
- 336 plasmablasts arose from the same population of naïve B cells as IgM and IgG1 isotype cells. In
- addition, the transient nature of this DENV-elicited IgA response suggests that these cells are
- 338 unable to take up residency in the bone marrow as long-lived plasma cells. While the biological
- 339 significance of this observation is unclear, the short-lived nature of serum-derive DENV-specific
- 340 IgA produced following both natural and experimental DENV infection has interesting
- 341 implications from an epidemiological and serosurveillance perspective.
- 342

343 There are some limitations of this study to consider. Firstly, the relativity small number of

- subjects included in this analysis limits the generalizability of the observations. Secondly, the
- 345 virus used in this study is delivered by intradermal injection rather than by an infected mosquito.
- 346 The presence of mosquito saliva and/or salivary proteins (MSPs) has been shown to impact the
- kinetics and magnitude of DENV viremia in several experimental models of DENV infection
- 348 [29], and it is currently unclear how the absence of this signal impacts the virologic and clinical
- 349 progression of DENV infection in humans.
- 350

In conclusion, we have demonstrated the ability to safely infect flavivirus naïve volunteers with an under-attenuated DENV-3 strain CH53489. This infection results in a dengue-like illness with symptoms, clinical lab abnormalities, and immune responses consistent with an uncomplicated natural DENV infection. We demonstrated the magnitude and frequency of symptoms and immunologic features correlated with peak viremia titers. The acute/innate immune response to CH53489 is evident as early as 6 days post infection and persists through at least 10 days post infection, with the induction of an adaptive anti-DENV immune response evident 14 days post

358 infection. These results provide hitherto unachievable insight into the kinetics and composition

of DENV-3 elicited immune responses in flavivirus naïve individuals and provide an array of
 DENV-elicited biomarkers that can inform the development and characterization of anti-DENV
 countermeasures.

- 362
- 363

#### 364 MATERIALS AND METHODS

365

366 Dengue human infection model. The Dengue Human Infection Model and associated analysis 367 was approved by the State University of New York Upstate Medical University (SUNY-UMU) 368 and the Department of Defense's Human Research Protection Office. This phase 1, open-label 369 study (ClinicalTrials.gov identifier: NCT04298138) was conducted between August 2020 and 370 July 2021 at the State University of New York, Upstate Medical University (SUNY-UMU) in 371 Syracuse, New York. Participants received a single subcutaneous inoculation of  $0.7 \times 10^3$  PFU 372  $(0.5\text{ml of a } 0.7 \times 10^3 \text{ PFU solution})$  of the CH53489 DENV-3 infection strain virus manufactured 373 at the WRAIR Pilot Bioproduction Facility, Silver Spring, MD (US FDA Investigational New 374 Drug 19321). All participants were pre-screened to ensure an absence of preexisting flavivirus 375 using the Euroimmun dengue, West Nile, and Zika IgG ELISA kits (Lübeck, Germany). Subjects 376 were monitored in an outpatient setting unless the hospitalization criteria were met. 377 Criteria for subject hospitalization included fever of > 101 at 2 time points at least 4 hours apart, 378 headache  $\geq$  grade 2, eye pain  $\geq$  grade 2, bone pain > grade 2, joint pain > grade 2, abdominal 379 pain > grade 2, muscle pain > grade 2, nausea and/or vomiting > grade 2, liver function tests 380 (ALT, AST) > grade 2, leukopenia > grade 2, thrombocytopenia ≥ grade 2, fatigue ≥ grade 2, or 381 the presence any symptoms determined by the PI to warrant hospital admission. Study 382 participants were discharged when the following criteria were met: no fever (< 100.4°F), 383 laboratory parameters resolving and were  $\leq$  grade 2 (at clinician discretion), and clinical 384 symptoms were resolving and were  $\leq$  grade 2 (at clinician discretion). Quantitative DENV-3 385 specific reverse-transcriptase polymerase chain reaction (RT-PCR) was performed using 386 previously published techniques [30]. Serum NS1 antigen levels were quantified using a 387 Euroimmun dengue NS1 ELISA kit (Lübeck, Germany). 388

389 **DENV-3 virion-capture ELISA.** DENV-3 reactive serum IgM/IgA/IgG levels were assessed 390 using a flavivirus capture ELISA protocol. In short, 96 well NUNC MaxiSorb flat-bottom plates

- 391 were coated with 2  $\mu$ g/ml flavivirus group-reactive mouse monoclonal antibody 4G2 (Envigo
- Bioproducts, Inc.) diluted in borate saline buffer. Plates were washed and blocked with 0.25%
- BSA +1% Normal Goat Serum in PBS after overnight incubation. DENV-3 (strain CH53489)
   was captured for 2 hours, followed by extensive washing. Serum samples were serially diluted
- four-fold, plated and incubated for 1 hour at room temperature on the captured virus. DENV-
- 395 rour-rou, plated and includated for 1 nour at room temperature on the captured virus. DENV-396 specific IgM/IgG/IgA levels were quantified using anti-human IgM HRP (Seracare, 5220-0328),
- 397 anti-human IgG HRP (Southern BioTech, 2044-0), and anti-human IgA HRP (Biolegend,
- 398 411,002). Secondary antibody binding was quantified using the TMB Microwell Peroxidase
- 399 Substrate System (KPL, cat. #50-76-00) and Synergy HT plate reader. DENV-3 (strain
- 400 CH53489) was propagated in Vero cells and purified by ultracentrifugation through a 30%
- 401 sucrose solution. End-point titers were determined as the reciprocal of the final dilution at which
- 402 the optical density (OD) was greater than  $2 \times$  of a pool of control flavivirus naïve serum at the
- same dilution. Day of seroconversion was defined as the day at which a participant's end-point
- 404 titer exceeded that of their respective day 0 sample

Anti-NS1 opsonization assay. DENV-3 NS1 expressing CEM.NK<sup>R</sup> cells (fig. S3) were stained

- 405 406
- 407 with a 1:50 dilution of heat-inactivated serum diluted in PBS at room temperature for 30 min. 408 Cells were extensively washed, then stained with goat anti-human IgA AF647 (2050-31, 409 Southern Biotech), goat anti-human IgG AF467 (2040-31, Southern Biotech), or goat anti-human 410 IgM AF647(2020-31, Southern Biotech). Flow cytometry analysis was performed on a BD 411 LSRII instrument, and data analyzed using FlowJo v10.2 software (Treestar). Reported MFI 412 values are background subtracted, with background defined as the signal observed staining DENV-3 NS1 expressing CEM.NK<sup>R</sup> cells in the absence of serum. Day of seroconversion was 413 414 defined as the day at which a participant's background-subtracted NS1 specific MFI increased by 415 at least  $2 \times$  over their respective day 0 value. 416 417 Serum cytokine analysis. The abundance of cytokines/chemokines in patient serum was 418 assessed using the MSD human U-PLEX Viral Combo 1 kit and the MESO QuickPlex SQ 120 419 instrument (MESO Scale Diagnostics, Rockville, MD) according to the manufacture's 420 recommendation. 421 422 IFN-Y ELISPOT. Cryopreserved PBMC were thawed, washed twice, and placed in RPMI 1640 423 medium (Corning, Tewksbury, MA, USA) supplemented with 10% heat-inactivated fetal calf 424 serum (Corning, 35-010-CV), L-glutamine (Lonza, Basel, Switzerland), and 425 Penicillin/Streptomycin (Gibco, Waltham, MA, USA). Cellular viability was assessed by trypan 426 blue exclusion and cells were resuspended at a concentration of  $5 \times 10^6$ /mL and rested overnight 427 at 37 °C. After resting, viable PBMC were washed, counted, and resuspended at a concentration 428 of  $1 \times 10^{6}$ /mL in complete cell culture media. Next, 100 µL of this cell suspension was mixed 429 with 100  $\mu$ L of the individual peptide pools listed in **Supplemental Table 11** and diluted to a 430 final concentration 1  $\mu$ g/mL/peptide (DMSO concentration 0.5%) in complete cell culture media. 431 This cell and peptide mixture was loaded onto a 96-well PVDF plate coated with anti-IFN- $\gamma$ 432 (3420-2HW-Plus, Mabtech, Nacka, Sweden) and cultured overnight. Controls for each 433 participant included 0.5% DMSO alone (negative) and anti-CD3 (positive). After overnight 434 incubation, the ELISPOT plates were washed and stained with anti-IFN-y-biotin followed by streptavidin-conjugated HRP (3420-2HW-Plus, Mabtech). Plates were developed using TMB 435 436 substrate and read using a CTL-ImmunoSpot<sup>®</sup> S6 Analyzer (Cellular Technology Limited, 437 Shaker Heights, OH, USA). All peptide pools were tested in duplicate, and the adjusted mean 438 was reported as the mean of the duplicate experimental wells after subtracting the mean value of 439 the negative (DMSO only) control wells. Individuals were considered reactive to a peptide pool 440 when the background-subtracted response was >50 spot forming cells (SFC)/10<sup>6</sup> PBMC. All data
- 441 were normalized based on the number of cells plated per well and are presented herein as
- 442 SFC/10<sup>6</sup> PBMC.
- 443
- RNA sequencing library preparation and sequencing. Whole blood was collected from all
  study participants using PAXgene RNA collection tubes (BD) and frozen at -20° C until
  analyzed. RNA was recovered from the collection tubes using the Qiagen PAXgene Blood RNA
  isolation Kit and sequencing libraries created using Illumina Stranded Total RNA Prep with
  Ribo-Zero Plus and IDT-Ilmn RNA UD Indexes SetA. Final library QC and quantification was
  performed using a Bioanalyizer (Agilent) and DNA 1000 reagents. Libraries were pooled at an

equimolar ratio and sequenced on a 300 cycle Novaseq 6000 instrument using v1.5 S4 reagentset.

452

453 **RNA sequencing gene expression analysis.** Raw reads from demultiplexed FASTQ files were 454 mapped to the human reference transcriptome (Ensembl, Home sapiens, GRCh38) using Kallisto 455 [31] version 0.46.2. Transcript-level counts and abundance data were imported and summarized 456 in R (version 4.0.2) using the TxImport package [32] and TMM normalized using the package 457 EdgeR [33, 34]. Differential gene expression analysis performed using linear modeling and 458 Bayesian statistics in the R package Limma [35]. Genes with a  $\log_2$  fold change of >2 and a 459 Benjamini-Hochberg adjusted p-value < 0.01 were considered significant. Gene module scores 460 were calculated by summing the TMM normalized abundance (TPM) of the genes highlighted as 461 belonging to either Module 1 or Module 2 for all samples. 462 463 BCR clonotype identification and annotation from bulk RNAseq. Raw FASTQ files were 464 filtered to contain only pair-end reads and to remove any Illumina adaptor contamination and 465 low-quality reads using Trimmomatic (v0.39) [36]. Pair-end reads were subsequently analyzed 466 using MiXCR (v3.0.3) using the RNA-seq/non-targeted genomic analysis pipeline [37, 38]. 467 468 Flow cytometry and cell sorting. Cryopreserved PBMC were thawed and placed in RPMI 1640 469 medium (Corning, Tewksbury, MA, USA) supplemented with 10% heat-inactivated fetal calf 470 serum (Corning, 35-010-CV), L-glutamine (Lonza, Basel, Switzerland), and 471 Penicillin/Streptomycin (Gibco, Waltham, MA, USA). Cellular viability was assessed by trypan 472 blue exclusion. Surface staining for flow cytometry analysis and cell sorting was performed in 473 PBS supplemented with 2% FBS at room temperature. Aqua Live/Dead (ThermoFisher, L34957)

- 474 was used to exclude dead cells in all experiments. Antibodies and dilutions used for flow
- 475 cytometry analysis are listed in **Supplemental Table 12.** Cell sorting was performed on a BD
- 476 FACSAria III instrument, with cells sorted directly into 50 ul of complete cell culture media
- 477 supplemented with 20% FCS. Data analyzed using FlowJo v10.2 software (Treestar).
- 478
- 479 Single-cell RNA sequencing library generation. Flow-sorted viable CD3-CD56-CD14-
- 480 CD19+CD27+CD38+ plasmablast phenotype B cells were prepared for single-cell RNA
- 481 sequencing using the Chromium NextGEM Single-Cell 5' Reagent version 2 kit and Chromium
- 482 Single-Cell Controller (10x Genomics, CA) [39]. Approximately 2000–8000 cells per reaction
- 483 suspended at a density of 50–500 cells/µL in PBS plus 0.5% FBS were loaded for gel bead-in-
- 484 emulsion (GEM) generation and barcoding. Reverse transcription, RT-cleanup, and cDNA
- amplification were performed to isolate and amplify cDNA for enriched V(D)J library
- 486 construction according to the manufacturer's protocol. Libraries were constructed using the
- 487 Chromium Single-Cell 5' reagent kit, V(D)J Human B Cell Enrichment Kit, and Dual Index Kit
- 488 (10x Genomics, CA) according to the manufacturer's protocol.
- 489
- 490 Single-cell RNA sequencing library Sequencing. scRNAseq BCR V(D)J enriched libraries
- 491 were sequenced on an Illumina NextSeq 2000 instrument using the 300 cycle P1 reagent kit.
- 492 Libraries were balanced to allow for ~10,000 reads/cell for BCR V(D)J enriched libraries.
- 493 Sequencing parameters were set for 150 cycles for Read1, 10 cycles for Index1, 10 cycles for
- 494 Index2, and 150 cycles for Read2. Prior to sequencing, library quality and concentration were

495 assessed using an Agilent 4200 TapeStation with High Sensitivity D5000 ScreenTape Assay
 496 according to the manufacturer's recommendations.

497

498 Immunoglobulin sequence analysis. Sorted B cell immunoglobulin clonotype identification,

alignment, and annotation was performed using the 10x Genomics Cell Ranger pipeline [39]

- 500 Sample demultiplexing and clonotype alignment was performed using the Cell Ranger software
- 501 package (10x Genomics, CA, v5.0.0) and bcl2fastq2 (Illumina, CA, v2.20) according to the
- manufacturer's recommendations, using the default settings and mkfastq/vdj commands,
   respectively. Immunoglobulin clonotype alignment was performed against a filtered human
- respectively. Immunoglobulin clonotype alignment was performed against a filtered human
   V(D)J reference library. Paired immunoglobulin hypermutation burden was assessed using the
- 505 software package BRILIA [40], and clonal lineages defined and visualized using the enclone
- 506 software suite from 10xGenomics.
- 507
- 508 Statistical analysis. All statistical analyses other than RNAseq gene expression analysis was
   509 performed using GraphPad Prism 9 Software (GraphPad Software, La Jolla, CA). A P-
- 510 value  $\square < \square 0.05$  was considered significant.
- 511 512

## 513 ACKNOWLEDGEMENTS

514

515 We gratefully acknowledge excellent technical assistance provided by Karen Gentile of the

516 Upstate Medical University Molecular Analysis Core (MAC), Lisa Phelps of the SUNY Upstate

- 517 Medical University Flow Cytometry Core, Holly Chanatry, and the members of the Institute for
- 518 Global Health and Translational Science (IGHTS) of SUNY Upstate Medical University. We
- 519also acknowledge Calli Rooney from the US Army. We also wish to thank all the study
- 520 participants for making this study possible. The following reagents were obtained through BEI
- 521 Resources, NIAID, NIH: Peptide Array, DENV-3 Sleman/1978, E protein (NR-511), DENV-3
- 522 Philippines/H87/1956, E protein (NR-9228), DENV-1 Philippines/H87/1956, NS1 protein (NR-
- 523 2753), DENV-3 Philippines/H87/1956, NS3 protein (NR-2754), DENV-3 Philippines/H87/1956,
- NS5 protein (NR-4204). The opinions or assertions contained herein are the private views of the authors and are not to be construed as reflecting the official views of the US Army or the US
- 526 Department of Defense. Material has been reviewed by the Walter Reed Army Institute of
- 527 Research. There is no objection to its presentation and/or publication. The investigators have
- adhered to the policies for protection of human participants as prescribed in AR 70-25.
- 529
- 530 **Funding:** Funding for this research was provided by the Department of Defense, Medical
- 531 Research and Material Command, the Military Infectious Disease Research Program, and the
- 532 State of New York.
- 533
- Author contributions. Conceptualization: L.W., M.D.K, R.G.J., T.P.E., and S.J.T. Formal
  analysis: L.W., A.T.W. Funding acquisition: H.F, R.G.J., T.P.E., and S.J.T. Investigation:
  A.T.W., J.Q.L., K.N., H.S.F., M.W., C.G., M.D.K., L.W., T.P.E., S.J.T. Resources: H.F., R.G.J.,
- 537 J.R.C. Visualization: K.N., A.T.W. Writing original draft: A.T.W., S.J.T. Writing review &
- 538 editing: all authors
- 539
- 540 **Competing interests:** All authors: No reported conflicts of interest.

511		
541	D	
542	Data	availability. The authors declare that all data supporting the findings of this study are
543	availa	ble within this article and its Supplementary Information files, or from the corresponding
544	autho	r upon reasonable request. RNAseq gene expression data have been deposited in the NCBI
545	Gene	Expression Omnibus (GEO GSE216328).
546		
547		
548	1.	Bhatt, S., et al., <i>The global distribution and burden of dengue</i> . Nature, 2013. <b>496</b> (7446):
549		p. 504-7.
550	2.	Shepard, D.S., et al., Economic impact of dengue illness in the Americas. Am J Trop Med
551		Hyg, 2011. <b>84</b> (2): p. 200-7.
552	3.	Guzman, M.G., et al., Dengue infection. Nat Rev Dis Primers, 2016. 2: p. 16055.
553	4.	Gubler, D.J., Aedes aegypti and Aedes aegypti-borne disease control in the 1990s: top
554		down or bottom up. Charles Franklin Craig Lecture. Am J Trop Med Hyg. 1989. 40(6):
555		p. 571-8.
556	5.	Iwamura, T., A. Guzman-Holst, and K.A. Murray, Accelerating invasion potential of
557	0.	disease vector Aedes aegypti under climate change. Nat Commun 2020 11(1): p 2130
558	6	World mosquito program <i>Facts sheet Dengue</i> . [cited 2021 27 April]: Available from:
559	0.	https://www.worldmosquitoprogram.org/sites/default/files/2020-
560		11/WMP%20dengue_0 ndf
561	7	Vaughn DW et al Dengue viremia titer antibody response pattern and virus serotype
562	7.	correlate with disease severity. I Infect Dis 2000 <b>181</b> (1): p. 2-9
563	8	Anderson K B et al A shorter time interval between first and second dengue infections
564	0.	is associated with protection from clinical illness in a school-based cohort in Thailand I
565		Infact Dis 2014 <b>200</b> (3): p. 360.8
566	0	Montova M et al. Symptomatic versus inapparent outcome in repeat dengue virus
567	9.	infactions is influenced by the time interval between infactions and study year. DLoS Nogl
568		Trop Dis 2012 7(8): p o2257
560	10	Curren M.C. M. Alverez and S.P. Helsterd Secondary infection as a risk factor for
509	10.	Guzinan, M.G., M. Alvarez, and S.B. Haistead, <i>Secondary injection as a risk juctor for</i>
570		dengue nemorrhagic jever/dengue snock synarome: an historical perspective and role of
5/1	11	antibody-dependent enhancement of infection. Arch virol, 2013. 158(7): p. 1445-59.
572	11.	Srikiatknachorn, A., et al., <i>Natural history of plasma leakage in dengue nemorrhagic</i>
5/3		<i>fever: a serial ultrasonographic study.</i> Pediatr Infect Dis J, 2007. <b>26</b> (4): p. 283-90;
574	10	discussion 291-2.
575	12.	Rajapakse, S., et al., Prophylactic and therapeutic interventions for bleeding in dengue: a
576		systematic review. Trans R Soc Trop Med Hyg, 2017. <b>111</b> (10): p. 433-439.
577	13.	Wong, J.G., et al., Identifying Adult Dengue Patients at Low Risk for Clinically
578		<i>Significant Bleeding</i> . PLoS One, 2016. <b>11</b> (2): p. e0148579.
579	14.	Capeding, M.R., et al., <i>Clinical efficacy and safety of a novel tetravalent dengue vaccine</i>
580		in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled
581		<i>trial</i> . Lancet, 2014. <b>384</b> (9951): p. 1358-65.
582	15.	Villar, L., et al., Efficacy of a tetravalent dengue vaccine in children in Latin America. N
583		Engl J Med, 2015. <b>372</b> (2): p. 113-23.
584	16.	World Health, O., Dengue vaccine: WHO position paper, July 2016 - recommendations.
585		Vaccine, 2017. <b>35</b> (9): p. 1200-1201.

586 17. Biswal, S., et al., Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and 587 Adolescents. N Engl J Med, 2019. 381(21): p. 2009-2019. 588 Biswal, S., et al., Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 18. 589 years: a randomised, placebo-controlled, phase 3 trial. Lancet, 2020. 395(10234): p. 590 1423-1433. 591 19. Takeda's QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in 592 Indonesia for Use Regardless of Prior Dengue Exposure. August 22, 2022: [Available 593 from: https://www.takeda.com/newsroom/newsreleases/2022/takedas-qdenga-dengue-594 tetravalent-vaccine-live-attenuated-approved-in-indonesia-for-use-regardless-of-prior-595 dengue-exposure/. 596 Thomas, S.J. and T.P. Endy, Current issues in dengue vaccination. Curr Opin Infect Dis, 20. 597 2013. 26(5): p. 429-34. 598 21. Low, J.G., E.E. Ooi, and S.G. Vasudevan, Current Status of Dengue Therapeutics 599 Research and Development. J Infect Dis, 2017. 215(suppl\_2): p. S96-S102. 600 22. Endy, T.P., et al., A Phase 1, Open-Label Assessment of a Dengue Virus-1 Live Virus 601 Human Challenge Strain. J Infect Dis, 2021. 223(2): p. 258-267. 602 23. Mammen, M.P., et al., Evaluation of dengue virus strains for human challenge studies. 603 Vaccine, 2014. 32(13): p. 1488-94. 604 Sun, W., et al., *Experimental dengue virus challenge of human subjects previously* 24. 605 vaccinated with live attenuated tetravalent dengue vaccines. J Infect Dis, 2013. 207(5): p. 606 700-8. 607 25. Waickman, A.T., et al., Transcriptional and clonal characterization of B cell plasmablast diversity following primary and secondary natural DENV infection. EBioMedicine, 2020. 608 609 **54**: p. 102733. 610 26. Waickman, A.T., et al., Temporally integrated single cell RNA sequencing analysis of 611 PBMC from experimental and natural primary human DENV-1 infections. PLoS Pathog, 612 2021. **17**(1): p. e1009240. 613 27. Rouers, A., et al., CD27(hi)CD38(hi) plasmablasts are activated B cells of mixed origin 614 with distinct function. iScience, 2021. 24(5): p. 102482. 615 Robinson, M.L., et al., Magnitude and kinetics of the human immune cell response 28. 616 associated with severe dengue progression by single-cell proteomics. bioRxiv, 2022: p. 617 2022.09.21.508901. 618 McCracken, M.K., et al., Route of inoculation and mosquito vector exposure modulate 29. 619 dengue virus replication kinetics and immune responses in rhesus macaques. PLoS Negl 620 Trop Dis, 2020. **14**(4): p. e0008191. Houng, H.S., et al., Development of a fluorogenic RT-PCR system for quantitative 621 30. 622 identification of dengue virus serotypes 1-4 using conserved and serotype-specific 3' 623 noncoding sequences. J Virol Methods, 2001. 95(1-2): p. 19-32. 624 31. Bray, N.L., et al., Erratum: Near-optimal probabilistic RNA-seq quantification. Nat 625 Biotechnol. 2016. 34(8): p. 888. 626 Soneson, C., M.I. Love, and M.D. Robinson, Differential analyses for RNA-seq: 32. 627 transcript-level estimates improve gene-level inferences. F1000Res, 2015. 4: p. 1521. 628 Robinson, M.D., D.J. McCarthy, and G.K. Smyth, edgeR: a Bioconductor package for 33. 629 differential expression analysis of digital gene expression data. Bioinformatics, 2010. 630 26(1): p. 139-40.

- 34. McCarthy, D.J., Y. Chen, and G.K. Smyth, *Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation*. Nucleic Acids Res, 2012.
   40(10): p. 4288-97.
- Ritchie, M.E., et al., *limma powers differential expression analyses for RNA-sequencing and microarray studies.* Nucleic Acids Res, 2015. 43(7): p. e47.
- 636 36. Bolger, A.M., M. Lohse, and B. Usadel, *Trimmomatic: a flexible trimmer for Illumina*637 *sequence data.* Bioinformatics, 2014. **30**(15): p. 2114-20.
- 638 37. Bolotin, D.A., et al., *MiXCR: software for comprehensive adaptive immunity profiling.*639 Nat Methods, 2015. **12**(5): p. 380-1.
- Bolotin, D.A., et al., Antigen receptor repertoire profiling from RNA-seq data. Nat
  Biotechnol, 2017. 35(10): p. 908-911.
- 642 39. Zheng, G.X., et al., *Massively parallel digital transcriptional profiling of single cells*. Nat
  643 Commun, 2017. 8: p. 14049.
- 40. Lee, D.W., et al., *BRILIA: Integrated Tool for High-Throughput Annotation and Lineage Tree Assembly of B-Cell Repertoires.* Front Immunol, 2016. 7: p. 681.
- 646
- 647
- 648

#### 649

### 650 FIGURE LEGENDS

651

Figure 1. Viral kinetics of CH53489 challenge. A) DENV-3 RNA content in serum as assessed
by qRT-PCR, B) Infectious DENV content in serum as assessed Vero cell plaque assay., C) NS1
protein content in serum as assessed by ELISA, D) Comparison of RNAemia, viremia, and NS1
antigenemia onset in all study participants, E) Comparison of peak RNAemia, viremia, and NS1
antigenemia in all study participants. ns not significant, \*\* p < 0.01, \*\*\*\* p< 0.0001, paired 1</li>
way ANOVA with correction for multiple comparisons

658 659

660 Figure 2. Timing and severity of clinically significant adverse events in response to

- 661 CH53489 challenge. A) Rash, B) Fatigue, C) Headache, D) Fever
- 662 663

## **Figure 3. Timing and magnitude of clinical lab abnormalities following CH53489 challenge**.

A) ALT, B) AST, C) HCT, D) WBC, E) Neutrophil count, F) Platelet count. All results shown
 relative to screening visit value

- 667
- 668

### 669 Figure 4. Kinetics and specificity of DENV-3 specific immunity elicited by CH53489

- 670 **challenge. A**) Antibody endpoint titers using virion-capture ELISA. **B**) Day of virion-specific
- IgM, IgA, and IgG seroconversion. C) Opsonizing anti-NS1 antibody staining using DENV-2
- 672 NS1 expressing CEM.NK<sup>R</sup> cells **D**) Day of DENV-2 NS1-specific IgM, IgA, and IgG
- 673 seroconversion. **E**) Antigen specific breakdown of days 0, 28, and 90 DENV-3 specific cellular
- 674 immunity. Dashed line indicates 50 SFC/ $10^6$  PBMC.
- 675

676	Figure 5. Kinetics and composition of DENV-3 elicited inflammation. A) PCA plot of
677	RNAseq analysis of whole blood obtained on days 0, 6, 8, 10, 14, and 28 post CH53489
678	infection. Points colored by sample collection day. <b>B</b> ) Volcano plot showing differential gene
679	expression day 0 vs day 6 C) day 0 vs day 8 D) day 0 vs day 10 and E) day 0 vs day 14 post
680	infection with select statistically and biologically significant genes highlighted. Genes with a
681	$\log_2$ fold change of >2 and an adjusted n-value < 0.01 were considered significant <b>F</b> ) Overlap of
682	Differentially Expressed Genes (DEG) observed on days 6.8, 10 and 14 post CH53489
683	infection <b>C</b> ) Kinetics of previously defined inflammatory gene module expression across all 9
68 <i>1</i>	study participants and 6 time points. H) Identification and quantification of unique IGH clones
685	across all 9 study participants and 6 time points from the unenriched RNAsea data using
686	MiXCR
687	MIACK.
688	Figure 6 Isolation and cloual characterization of $\mathbf{DFNV}_{-3}$ elicited plasmables (A)
680	Identification and post sort purity of DENV 3 aligited plasmablasts <b>B</b> ) Isotype distribution of
600	DENIV 3 aligited plasmablasts C) Clonal divergity and isotype distribution of all DENIV 3
601	aligited plasmablasts <b>D</b> ) Clonel divergity and isotype distribution of avanded $(n > 3)$ DENV 3
602	elicited plasmablasts <b>E</b> ) Cional diversity and isotype distribution of EXPanded ( $n > 3$ ) DENV-3 elicited plasmablasts <b>E</b> ) Sometic hypermutation burden of DENV-3 elicited plasmablasts
603	separated by isotype $****$ p < 0.0001 one way ANOVA with correction for multiple
60 <i>1</i>	comparisons
605	comparisons.
696	Figure 7 Correlation analysis of selection virologic clinical and immunologic features post
697	<b>CH53489 challenge</b> $A$ ) Correlation matrix Spearman correlation Only interactions with a $n < 1000$
698	0.05 shown <b>B</b> ) Peak viremia vs total days with fever for each subject <b>C</b> ) Peak NS1 antigen
699	levels vs total days with fever for each subject $\mathbf{D}$ ) Peak viremia vs virion-specific IgG AUC $\mathbf{E}$ )
700	Peak NS1 antigen levels vs NS1-specific IoG AUC
701	reak rust anagen levels visitust speeme igo riec
702	
703	
704	
705	
706	
707	
708	
709	
710	
711	
712	
713	
714	
715	
716	
717	
718	Table 1. IPA analysis of differentially expressed genes defined by RNAseq on days 6, 8, 10,
719	and 14 post CH58349 infection
720	-

Comparison Ingenuity Canonical Pathways	
---	--

-log(p-value) Ratio z-score

Day 0 vs Day 6	Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza	1.98E+01	1.98E-01	3.638
Day 0 vs Day 6	Interferon Signaling	1.71E+01	3.33E-01	2.887
Day 0 vs Day 6	Activation of IRF by Cytosolic Pattern Recognition Receptors	9.22E+00	1.38E-01	1.667
Day 0 vs Day 6	Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses	7.97E+00	7.05E-02	2
Day 0 vs Day 6	Coronavirus Pathogenesis Pathway	6.80E+00	5.42E-02	-2.111
Day 0 vs Day 6	Role of PKR in Interferon Induction and Antiviral Response	5.35E+00	5.88E-02	2.646
Day 0 vs Day 6	Granulocyte Adhesion and Diapedesis	4.31E+00	4.23E-02	NaN
Day 0 vs Day 6	Death Receptor Signaling	4.29E+00	6.25E-02	2.449
Day 0 vs Day 6	Retinoic acid Mediated Apoptosis Signaling	4.25E+00	8.33E-02	2.236
Day 0 vs Day 6	Agranulocyte Adhesion and Diapedesis	3.94E+00	3.74E-02	NaN
Day 0 vs Day 8	Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza	1.70E+01	1.98E-01	4.123
Day 0 vs Day 8	Interferon Signaling	1.35E+01	3.06E-01	2.714
Day 0 vs Day 8	Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses	1.03E+01	9.62E-02	2.828
Day 0 vs Day 8	Activation of IRF by Cytosolic Pattern Recognition Receptors	7.81E+00	1.38E-01	1.667
Day 0 vs Day 8	Granulocyte Adhesion and Diapedesis	6.36E+00	6.35E-02	NaN
Day 0 vs Day 8	Coronavirus Pathogenesis Pathway	6.03E+00	5.91E-02	-2.111
Day 0 vs Day 8	Complement System	4.51E+00	1.35E-01	1
Day 0 vs Day 8	Agranulocyte Adhesion and Diapedesis	4.24E+00	4.67E-02	NaN
Day 0 vs Day 8	Role of PKR in Interferon Induction and Antiviral Response	4.19E+00	5.88E-02	2.449
Day 0 vs Day 8	Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza	1.70E+01	1.98E-01	4.123
Day 0 vs Day 0				
Day 0 vs Day 3 Day 0 vs Day 10	Systemic Lupus Erythematosus In B Cell Signaling Pathway	2.14E+01	5.67E-02	2.828
Day 0 vs Day 10 Day 0 vs Day 10 Day 0 vs Day 10	Systemic Lupus Erythematosus In B Cell Signaling Pathway IL-15 Signaling	2.14E+01 2.04E+01	5.67E-02 6.63E-02	2.828 NaN
Day 0 vs Day 10 Day 0 vs Day 10 Day 0 vs Day 10 Day 0 vs Day 10	Systemic Lupus Erythematosus In B Cell Signaling Pathway IL-15 Signaling B Cell Receptor Signaling	2.14E+01 2.04E+01 1.79E+01	5.67E-02 6.63E-02 5.55E-02	2.828 NaN NaN
Day 0 vs Day 10 Day 0 vs Day 10 Day 0 vs Day 10 Day 0 vs Day 10 Day 0 vs Day 10	Systemic Lupus Erythematosus In B Cell Signaling Pathway IL-15 Signaling B Cell Receptor Signaling Communication between Innate and Adaptive Immune Cells	2.14E+01 2.04E+01 1.79E+01 1.35E+01	5.67E-02 6.63E-02 5.55E-02 3.88E-02	2.828 NaN NaN NaN
Day 0 vs Day 10 Day 0 vs Day 10	Systemic Lupus Erythematosus In B Cell Signaling Pathway IL-15 Signaling B Cell Receptor Signaling Communication between Innate and Adaptive Immune Cells Interferon Signaling	2.14E+01 2.04E+01 1.79E+01 1.35E+01 1.24E+01	5.67E-02 6.63E-02 5.55E-02 3.88E-02 2.78E-01	2.828 NaN NaN 2.53
Day 0 vs Day 10 Day 0 vs Day 10	Systemic Lupus Erythematosus In B Cell Signaling Pathway IL-15 Signaling B Cell Receptor Signaling Communication between Innate and Adaptive Immune Cells Interferon Signaling Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza	2.14E+01 2.04E+01 1.79E+01 1.35E+01 1.24E+01 1.10E+01	5.67E-02 6.63E-02 5.55E-02 3.88E-02 2.78E-01 1.40E-01	2.828 NaN NaN 2.53 3.464
Day 0 vs Day 10 Day 0 vs Day 10	Systemic Lupus Erythematosus In B Cell Signaling Pathway         IL-15 Signaling         B Cell Receptor Signaling         Communication between Innate and Adaptive Immune Cells         Interferon Signaling         Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza         Primary Immunodeficiency Signaling	2.14E+01 2.04E+01 1.79E+01 1.35E+01 1.24E+01 1.10E+01 7.59E+00	5.67E-02 6.63E-02 5.55E-02 3.88E-02 2.78E-01 1.40E-01 1.43E-01	2.828 NaN NaN 2.53 3.464 NaN
Day 0 vs Day 10 Day 0 vs Day 10	Systemic Lupus Erythematosus In B Cell Signaling Pathway IL-15 Signaling B Cell Receptor Signaling Communication between Innate and Adaptive Immune Cells Interferon Signaling Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza Primary Immunodeficiency Signaling Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses	2.14E+01 2.04E+01 1.79E+01 1.35E+01 1.24E+01 1.10E+01 7.59E+00 4.20E+00	5.67E-02 6.63E-02 5.55E-02 3.88E-02 2.78E-01 1.40E-01 1.43E-01 5.13E-02	2.828 NaN NaN 2.53 3.464 NaN 2
Day 0 vs Day 10 Day 0 vs Day 10	Systemic Lupus Erythematosus In B Cell Signaling Pathway IL-15 Signaling B Cell Receptor Signaling Communication between Innate and Adaptive Immune Cells Interferon Signaling Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza Primary Immunodeficiency Signaling Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses Activation of IRF by Cytosolic Pattern Recognition Receptors	2.14E+01 2.04E+01 1.79E+01 1.35E+01 1.24E+01 1.10E+01 7.59E+00 4.20E+00 3.61E+00	5.67E-02 6.63E-02 5.55E-02 3.88E-02 2.78E-01 1.40E-01 1.43E-01 5.13E-02 7.69E-02	2.828 NaN NaN 2.53 3.464 NaN 2 0.447
Day 0 vs Day 10 Day 0 vs Day 10	Systemic Lupus Erythematosus In B Cell Signaling Pathway         IL-15 Signaling         B Cell Receptor Signaling         Communication between Innate and Adaptive Immune Cells         Interferon Signaling         Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza         Primary Immunodeficiency Signaling         Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses         Activation of IRF by Cytosolic Pattern Recognition Receptors         Pyrimidine Deoxyribonucleotides De Novo Biosynthesis I	2.14E+01 2.04E+01 1.79E+01 1.35E+01 1.24E+01 1.10E+01 7.59E+00 4.20E+00 3.61E+00 3.01E+00	5.67E-02 6.63E-02 5.55E-02 3.88E-02 2.78E-01 1.40E-01 1.43E-01 1.43E-01 5.13E-02 7.69E-02 1.30E-01	2.828 NaN NaN 2.53 3.464 NaN 2 0.447 NaN
Day 0 vs Day 10 Day 0 vs Day 10	Systemic Lupus Erythematosus In B Cell Signaling Pathway IL-15 Signaling B Cell Receptor Signaling Communication between Innate and Adaptive Immune Cells Interferon Signaling Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza Primary Immunodeficiency Signaling Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses Activation of IRF by Cytosolic Pattern Recognition Receptors Pyrimidine Deoxyribonucleotides De Novo Biosynthesis I IL-15 Signaling	2.14E+01 2.04E+01 1.79E+01 1.35E+01 1.24E+01 1.10E+01 7.59E+00 4.20E+00 3.61E+00 3.01E+00 1.08E+02	5.67E-02 6.63E-02 5.55E-02 3.88E-02 2.78E-01 1.40E-01 1.43E-01 5.13E-02 7.69E-02 1.30E-01 2.05E-01	2.828 NaN NaN 2.53 3.464 NaN 2 0.447 NaN NaN
Day 0 vs Day 10 Day 0 vs Day 14	Systemic Lupus Erythematosus In B Cell Signaling Pathway IL-15 Signaling B Cell Receptor Signaling Communication between Innate and Adaptive Immune Cells Interferon Signaling Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza Primary Immunodeficiency Signaling Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses Activation of IRF by Cytosolic Pattern Recognition Receptors Pyrimidine Deoxyribonucleotides De Novo Biosynthesis I IL-15 Signaling B Cell Receptor Signaling	2.14E+01 2.04E+01 1.79E+01 1.35E+01 1.24E+01 1.10E+01 7.59E+00 4.20E+00 3.61E+00 3.01E+00 1.08E+02 9.91E+01	5.67E-02 6.63E-02 5.55E-02 3.88E-02 2.78E-01 1.40E-01 1.43E-01 5.13E-02 7.69E-02 1.30E-01 2.05E-01 1.71E-01	2.828 NaN NaN 2.53 3.464 NaN 2 0.447 NaN NaN NaN
Day 0 vs Day 0 Day 0 vs Day 10 Day 0 vs Day 11 Day 0 vs Day 14 Day 0 vs Day 14	Systemic Lupus Erythematosus In B Cell Signaling Pathway         IL-15 Signaling         B Cell Receptor Signaling         Communication between Innate and Adaptive Immune Cells         Interferon Signaling         Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza         Primary Immunodeficiency Signaling         Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses         Activation of IRF by Cytosolic Pattern Recognition Receptors         Pyrimidine Deoxyribonucleotides De Novo Biosynthesis I         IL-15 Signaling         B Cell Receptor Signaling         Systemic Lupus Erythematosus In B Cell Signaling Pathway	2.14E+01 2.04E+01 1.79E+01 1.35E+01 1.24E+01 1.10E+01 7.59E+00 4.20E+00 3.61E+00 3.01E+00 1.08E+02 9.91E+01 9.24E+01	5.67E-02 6.63E-02 5.55E-02 3.88E-02 2.78E-01 1.40E-01 1.43E-01 5.13E-02 7.69E-02 1.30E-01 2.05E-01 1.71E-01 1.49E-01	2.828 NaN NaN 2.53 3.464 NaN 2 0.447 NaN NaN NaN NaN
Day 0 vs Day 10 Day 0 vs Day 11 Day 0 vs Day 14 Day 0 vs Day 14 Day 0 vs Day 14	Systemic Lupus Erythematosus In B Cell Signaling Pathway         IL-15 Signaling         B Cell Receptor Signaling         Communication between Innate and Adaptive Immune Cells         Interferon Signaling         Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza         Primary Immunodeficiency Signaling         Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses         Activation of IRF by Cytosolic Pattern Recognition Receptors         Pyrimidine Deoxyribonucleotides De Novo Biosynthesis I         IL-15 Signaling         B Cell Receptor Signaling         Systemic Lupus Erythematosus In B Cell Signaling Pathway         Communication between Innate and Adaptive Immune Cells	2.14E+01 2.04E+01 1.79E+01 1.35E+01 1.24E+01 1.10E+01 7.59E+00 4.20E+00 3.61E+00 3.01E+00 1.08E+02 9.91E+01 9.24E+01 8.17E+01	5.67E-02 6.63E-02 5.55E-02 3.88E-02 2.78E-01 1.40E-01 1.43E-01 5.13E-02 7.69E-02 1.30E-01 2.05E-01 1.71E-01 1.49E-01 1.17E-01	2.828 NaN NaN 2.53 3.464 NaN 2 0.447 NaN NaN NaN NaN NaN NaN
Day 0 vs Day 10 Day 0 vs Day 14 Day 0 vs Day 14 Day 0 vs Day 14 Day 0 vs Day 14	Systemic Lupus Erythematosus In B Cell Signaling Pathway IL-15 Signaling B Cell Receptor Signaling Communication between Innate and Adaptive Immune Cells Interferon Signaling Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza Primary Immunodeficiency Signaling Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses Activation of IRF by Cytosolic Pattern Recognition Receptors Pyrimidine Deoxyribonucleotides De Novo Biosynthesis I IL-15 Signaling B Cell Receptor Signaling Systemic Lupus Erythematosus In B Cell Signaling Pathway Communication between Innate and Adaptive Immune Cells Kinetochore Metaphase Signaling Pathway	2.14E+01 2.04E+01 1.79E+01 1.35E+01 1.24E+01 1.10E+01 7.59E+00 4.20E+00 3.61E+00 3.01E+00 1.08E+02 9.91E+01 9.24E+01 8.17E+01 1.54E+01	5.67E-02 6.63E-02 5.55E-02 3.88E-02 2.78E-01 1.40E-01 1.43E-01 5.13E-02 7.69E-02 1.30E-01 2.05E-01 1.71E-01 1.49E-01 1.17E-01 1.62E-01	2.828 NaN NaN 2.53 3.464 NaN 2 0.447 NaN NaN NaN NaN NaN NaN NaN 3.207
Day 0 vs Day 10 Day 0 vs Day 14 Day 0 vs Day 14 Day 0 vs Day 14 Day 0 vs Day 14 Day 0 vs Day 14	Systemic Lupus Erythematosus In B Cell Signaling Pathway IL-15 Signaling B Cell Receptor Signaling Communication between Innate and Adaptive Immune Cells Interferon Signaling Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza Primary Immunodeficiency Signaling Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses Activation of IRF by Cytosolic Pattern Recognition Receptors Pyrimidine Deoxyribonucleotides De Novo Biosynthesis I IL-15 Signaling B Cell Receptor Signaling Systemic Lupus Erythematosus In B Cell Signaling Pathway Communication between Innate and Adaptive Immune Cells Kinetochore Metaphase Signaling Pathway Primary Immunodeficiency Signaling	2.14E+01 2.04E+01 1.79E+01 1.35E+01 1.24E+01 1.10E+01 7.59E+00 4.20E+00 3.61E+00 3.01E+00 1.08E+02 9.91E+01 9.24E+01 8.17E+01 1.54E+01 1.06E+01	5.67E-02 6.63E-02 5.55E-02 3.88E-02 2.78E-01 1.40E-01 1.43E-01 5.13E-02 7.69E-02 1.30E-01 1.71E-01 1.71E-01 1.49E-01 1.17E-01 1.62E-01 1.96E-01	2.828 NaN NaN 2.53 3.464 NaN 2 0.447 NaN NaN NaN NaN NaN NaN NaN NaN NaN Na
Day 0 vs Day 10 Day 0 vs Day 14 Day 0 vs Day 14	Systemic Lupus Erythematosus In B Cell Signaling Pathway         IL-15 Signaling         B Cell Receptor Signaling         Communication between Innate and Adaptive Immune Cells         Interferon Signaling         Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza         Primary Immunodeficiency Signaling         Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses         Activation of IRF by Cytosolic Pattern Recognition Receptors         Pyrimidine Deoxyribonucleotides De Novo Biosynthesis I         IL-15 Signaling         B Cell Receptor Signaling         Systemic Lupus Erythematosus In B Cell Signaling Pathway         Communication between Innate and Adaptive Immune Cells         Kinetochore Metaphase Signaling Pathway         Primary Immunodeficiency Signaling         Estrogen-mediated S-phase Entry	2.14E+01 2.04E+01 1.79E+01 1.35E+01 1.24E+01 1.10E+01 7.59E+00 4.20E+00 3.61E+00 3.01E+00 1.08E+02 9.91E+01 9.24E+01 8.17E+01 1.54E+01 1.06E+01 7.95E+00	5.67E-02 6.63E-02 5.55E-02 3.88E-02 2.78E-01 1.40E-01 1.43E-01 5.13E-02 7.69E-02 1.30E-01 2.05E-01 1.71E-01 1.49E-01 1.17E-01 1.62E-01 1.96E-01 2.69E-01	2.828 NaN NaN 2.53 3.464 NaN 2 0.447 NaN NaN NaN NaN NaN NaN NaN 3.207 NaN 2.646
Day 0 vs Day 10 Day 0 vs Day 14 Day 0 vs Day 14	Systemic Lupus Erythematosus In B Cell Signaling Pathway         IL-15 Signaling         B Cell Receptor Signaling         Communication between Innate and Adaptive Immune Cells         Interferon Signaling         Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza         Primary Immunodeficiency Signaling         Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses         Activation of IRF by Cytosolic Pattern Recognition Receptors         Pyrimidine Deoxyribonucleotides De Novo Biosynthesis I         IL-15 Signaling         B Cell Receptor Signaling         Systemic Lupus Erythematosus In B Cell Signaling Pathway         Communication between Innate and Adaptive Immune Cells         Kinetochore Metaphase Signaling Pathway         Primary Immunodeficiency Signaling         Estrogen-mediated S-phase Entry         Mitotic Roles of Polo-Like Kinase	2.14E+01 2.04E+01 1.79E+01 1.35E+01 1.24E+01 1.10E+01 7.59E+00 4.20E+00 3.61E+00 3.01E+00 1.08E+02 9.91E+01 9.24E+01 8.17E+01 1.54E+01 1.06E+01 7.95E+00 7.29E+00	5.67E-02 6.63E-02 5.55E-02 3.88E-02 2.78E-01 1.40E-01 1.43E-01 5.13E-02 7.69E-02 1.30E-01 1.71E-01 1.49E-01 1.49E-01 1.62E-01 1.96E-01 2.69E-01 1.36E-01	2.828 NaN NaN 2.53 3.464 NaN 2 0.447 NaN NaN NaN NaN NaN NaN 3.207 NaN 2.646 1.414
Day 0 vs Day 10 Day 0 vs Day 14 Day 0 vs Day 14	Systemic Lupus Erythematosus In B Cell Signaling Pathway         IL-15 Signaling         B Cell Receptor Signaling         Communication between Innate and Adaptive Immune Cells         Interferon Signaling         Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza         Primary Immunodeficiency Signaling         Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses         Activation of IRF by Cytosolic Pattern Recognition Receptors         Pyrimidine Deoxyribonucleotides De Novo Biosynthesis I         IL-15 Signaling         B Cell Receptor Signaling         Systemic Lupus Erythematosus In B Cell Signaling Pathway         Communication between Innate and Adaptive Immune Cells         Kinetochore Metaphase Signaling Pathway         Primary Immunodeficiency Signaling         Estrogen-mediated S-phase Entry         Mitotic Roles of Polo-Like Kinase         Cyclins and Cell Cycle Regulation	2.14E+01 2.04E+01 1.79E+01 1.35E+01 1.35E+01 1.24E+01 1.10E+01 7.59E+00 4.20E+00 3.61E+00 3.01E+00 1.08E+02 9.91E+01 9.24E+01 8.17E+01 1.54E+01 1.06E+01 7.95E+00 7.29E+00 6.37E+00	5.67E-02 6.63E-02 5.55E-02 3.88E-02 2.78E-01 1.40E-01 1.43E-01 5.13E-02 7.69E-02 1.30E-01 1.71E-01 1.49E-01 1.49E-01 1.49E-01 1.49E-01 1.62E-01 1.96E-01 1.36E-01 1.36E-01 1.07E-01	2.828 NaN NaN 2.53 3.464 NaN 2 0.447 NaN NaN NaN NaN NaN NaN NaN NaN 2.646 1.414 3

721





Mild

Moderate

Severe









medRxiv preprint doi: https://doi.org/10.1101/2022.10.24.22281454; this version posted October 31, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
 Figure 6



